JP6212045B2 - Ａｔｒキナーゼの阻害剤として有用な化合物を作製するためのプロセス - Google Patents

Ａｔｒキナーゼの阻害剤として有用な化合物を作製するためのプロセス Download PDF

Info

Publication number
JP6212045B2
JP6212045B2 JP2014533441A JP2014533441A JP6212045B2 JP 6212045 B2 JP6212045 B2 JP 6212045B2 JP 2014533441 A JP2014533441 A JP 2014533441A JP 2014533441 A JP2014533441 A JP 2014533441A JP 6212045 B2 JP6212045 B2 JP 6212045B2
Authority
JP
Japan
Prior art keywords
compound
formula
item
conditions
solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014533441A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014532054A5 (OSRAM
JP2014532054A (ja
Inventor
ジャン−ダミアン シャリエ，
ジャン−ダミアン シャリエ，
ジョン スタッドレー，
ジョン スタッドレー，
フランソワ イヴォンヌ テオドラ マリー ピラール，
フランソワ イヴォンヌ テオドラ マリー ピラール，
スティーブン ジョン デュラント，
スティーブン ジョン デュラント，
ベンジャミン ジョセフ リトラー，
ベンジャミン ジョセフ リトラー，
ロバート マイケル ユース，
ロバート マイケル ユース，
デイビッド アンドリュー シーセル，
デイビッド アンドリュー シーセル，
ポール アンジェル，
ポール アンジェル，
アルマンド ウルビーナ，
アルマンド ウルビーナ，
イー シー，
イー シー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of JP2014532054A publication Critical patent/JP2014532054A/ja
Publication of JP2014532054A5 publication Critical patent/JP2014532054A5/ja
Application granted granted Critical
Publication of JP6212045B2 publication Critical patent/JP6212045B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32—Oximes
    • C07C251/34—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C251/48—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atom of at least one of the oxyimino groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/06—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
JP2014533441A 2011-09-30 2012-09-28 Ａｔｒキナーゼの阻害剤として有用な化合物を作製するためのプロセス Expired - Fee Related JP6212045B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161541865P 2011-09-30 2011-09-30
US61/541,865 2011-09-30
PCT/US2012/058127 WO2013049726A2 (en) 2011-09-30 2012-09-28 Processes for making compounds useful as inhibitors of atr kinase

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2016221714A Division JP6317800B2 (ja) 2011-09-30 2016-11-14 Ａｔｒキナーゼの阻害剤として有用な化合物を作製するためのプロセス
JP2017148280A Division JP2017226676A (ja) 2011-09-30 2017-07-31 Ａｔｒキナーゼの阻害剤として有用な化合物を作製するためのプロセス

Publications (3)

Publication Number Publication Date
JP2014532054A JP2014532054A (ja) 2014-12-04
JP2014532054A5 JP2014532054A5 (OSRAM) 2015-11-12
JP6212045B2 true JP6212045B2 (ja) 2017-10-11

Family

ID=47019163

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2014533441A Expired - Fee Related JP6212045B2 (ja) 2011-09-30 2012-09-28 Ａｔｒキナーゼの阻害剤として有用な化合物を作製するためのプロセス
JP2016221714A Expired - Fee Related JP6317800B2 (ja) 2011-09-30 2016-11-14 Ａｔｒキナーゼの阻害剤として有用な化合物を作製するためのプロセス
JP2017148280A Withdrawn JP2017226676A (ja) 2011-09-30 2017-07-31 Ａｔｒキナーゼの阻害剤として有用な化合物を作製するためのプロセス
JP2019099224A Pending JP2019172684A (ja) 2011-09-30 2019-05-28 Ａｔｒキナーゼの阻害剤として有用な化合物を作製するためのプロセス

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2016221714A Expired - Fee Related JP6317800B2 (ja) 2011-09-30 2016-11-14 Ａｔｒキナーゼの阻害剤として有用な化合物を作製するためのプロセス
JP2017148280A Withdrawn JP2017226676A (ja) 2011-09-30 2017-07-31 Ａｔｒキナーゼの阻害剤として有用な化合物を作製するためのプロセス
JP2019099224A Pending JP2019172684A (ja) 2011-09-30 2019-05-28 Ａｔｒキナーゼの阻害剤として有用な化合物を作製するためのプロセス

Country Status (23)

Country Link
US (4) US9035053B2 (OSRAM)
EP (4) EP2751097A2 (OSRAM)
JP (4) JP6212045B2 (OSRAM)
KR (2) KR102013133B1 (OSRAM)
CN (2) CN103987709B (OSRAM)
AR (1) AR088092A1 (OSRAM)
AU (3) AU2012315615A1 (OSRAM)
BR (1) BR112014007721B1 (OSRAM)
CA (2) CA3124539A1 (OSRAM)
ES (1) ES2751741T3 (OSRAM)
HR (1) HRP20191641T1 (OSRAM)
HU (1) HUE046429T2 (OSRAM)
IL (3) IL231771A0 (OSRAM)
IN (1) IN2014KN00929A (OSRAM)
MX (1) MX353461B (OSRAM)
PL (1) PL2940017T3 (OSRAM)
PT (1) PT2940017T (OSRAM)
RS (1) RS59337B1 (OSRAM)
RU (2) RU2018147217A (OSRAM)
SG (2) SG10201606774UA (OSRAM)
TW (3) TWI625328B (OSRAM)
WO (1) WO2013049726A2 (OSRAM)
ZA (1) ZA201402625B (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017061519A (ja) * 2011-09-30 2017-03-30 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼの阻害剤として有用な化合物を作製するためのプロセス

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG172248A1 (en) 2008-12-19 2011-07-28 Vertex Pharma Pyrazine derivatives useful as inhibitors of atr kinase
US8969356B2 (en) 2010-05-12 2015-03-03 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
JP2013529200A (ja) 2010-05-12 2013-07-18 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ阻害剤として有用な化合物
JP5856151B2 (ja) 2010-05-12 2016-02-09 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼ阻害剤として有用な２−アミノピリジン誘導体
EP2569287B1 (en) 2010-05-12 2014-07-09 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
MX2012013081A (es) 2010-05-12 2013-05-09 Vertex Pharma Compuestos utiles como inhibidores de cinasa atr.
US8962631B2 (en) 2010-05-12 2015-02-24 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
MX2013000103A (es) 2010-06-23 2013-06-13 Vertex Pharma Derivados de pirrolo-pirazina utiles como inhibidores de cinasa art.
MX2013011450A (es) * 2011-04-05 2014-02-03 Vertex Pharma Compuestos de aminopirazina utiles como inhibidores de la cinasa ataxia telangiectasia mutada y rad3 relacionados (atr).
JP2014520161A (ja) 2011-06-22 2014-08-21 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ阻害剤として有用な化合物
US9309250B2 (en) 2011-06-22 2016-04-12 Vertex Pharmaceuticals Incorporated Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors
US9096602B2 (en) 2011-06-22 2015-08-04 Vertex Pharmaceuticals Incorporated Substituted pyrrolo[2,3-B]pyrazines as ATR kinase inhibitors
US8853217B2 (en) 2011-09-30 2014-10-07 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
SG10201602515QA (en) 2011-09-30 2016-05-30 Vertex Pharma Treating pancreatic cancer and non-small cell lung cancer with atr inhibitors
EP2751088B1 (en) 2011-09-30 2016-04-13 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
AU2012315611A1 (en) 2011-09-30 2014-04-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
JP2015502925A (ja) 2011-11-09 2015-01-29 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼの阻害剤として有用なピラジン化合物
US8841450B2 (en) 2011-11-09 2014-09-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
WO2013071094A1 (en) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
EP2776421A1 (en) 2011-11-09 2014-09-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
EP2776422A1 (en) 2011-11-09 2014-09-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
NZ700580A (en) 2012-04-05 2016-07-29 Vertex Pharma Compounds useful as inhibitors of atr kinase and combination therapies thereof
WO2014055756A1 (en) 2012-10-04 2014-04-10 Vertex Pharmaceuticals Incorporated Method for measuring atr inhibition mediated increases in dna damage
US8912198B2 (en) 2012-10-16 2014-12-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
FI4190786T3 (fi) 2012-12-07 2025-05-23 Vertex Pharma Atr-kinaasin estäjinä käyttökelpoisia yhdisteitä
EP2970286A1 (en) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Inc. Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase
EP3077397B1 (en) 2013-12-06 2019-09-18 Vertex Pharmaceuticals Inc. 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof
HRP20200186T1 (hr) 2014-06-05 2020-05-29 Vertex Pharmaceuticals Inc. Radioaktivno obilježeni derivati 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-karboksamid spojeva koji se koriste kao inhibitori atr kinaze, priprava navedenih spojeva i njihovi različiti čvrsti oblici
JP6936007B2 (ja) 2014-06-17 2021-09-15 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ｃｈｋ１阻害剤とａｔｒ阻害剤との組み合わせを使用してがんを処置する方法
EP3355926B1 (en) 2015-09-30 2025-12-24 Vertex Pharmaceuticals Inc. Combination of dna damaging agents and atr inhibitors for use in a method for treating cancer using
IL313681A (en) * 2016-01-11 2024-08-01 Celator Pharmaceuticals Inc Inhibiting ataxia telangiectasia and rad3-related protein (atr)
US10301324B2 (en) 2016-04-12 2019-05-28 Atrin Pharmaceuticals LLC Ataxia telengiectasia and rad3-related (ATR) inhibitors and methods of their use
EA039513B1 (ru) * 2017-01-09 2022-02-04 Селатор Фармасьютикалз, Инк. Ингибитор атаксии-телеангиэкстазии и rad3-родственного белка (atr) и содержащие его липосомные композиции
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
JP2021508700A (ja) * 2017-12-29 2021-03-11 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒ阻害剤を使用するがん処置の方法
TWI827583B (zh) 2018-03-08 2024-01-01 美商英塞特公司 作為ＰＩ３Ｋ-γ抑制劑之胺基吡嗪二醇化合物
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
KR20210066837A (ko) 2018-09-26 2021-06-07 메르크 파텐트 게엠베하 암 치료를 위한 pd-1 안타고니스트, atr 억제제 및 백금화제의 조합
AU2019360608A1 (en) 2018-10-15 2021-06-03 Merck Patent Gmbh Combination therapy utilizing DNA alkylating agents and ATR inhibitors
AU2021367820A1 (en) 2020-10-26 2023-06-22 Merck Patent Gmbh Atr inhibitors for use in the treatment of viral infections
CN115703768B (zh) * 2021-08-13 2024-12-17 苏州爱科百发生物医药技术有限公司 用作atr激酶抑制剂的化合物
US20250026742A1 (en) * 2021-08-13 2025-01-23 Suzhou Ark Biopharmaceutical Co., Ltd. Compound as atr kinase inhibitor

Family Cites Families (223)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4309430A (en) 1980-06-27 1982-01-05 Merck & Co., Inc. Pyrazinyl-1,2,4-oxadiazole-5-ones, for treatment of edema, and processes for preparing same
JPS62270623A (ja) 1985-12-07 1987-11-25 Daicel Chem Ind Ltd ビス（４−アミノフエニル）ピラジンおよびその製法、ならびにポリイミドおよびその製法
JPS63208520A (ja) 1987-02-26 1988-08-30 Terumo Corp ピラジン誘導体を含有する血小板凝集抑制剤
US5329012A (en) 1987-10-29 1994-07-12 The Research Foundation Of State University Of New York Bis(acyloxmethyl)imidazole compounds
JPH0272370A (ja) 1988-09-07 1990-03-12 Konica Corp 電子写真感光体
JPH0272372A (ja) 1988-09-07 1990-03-12 Konica Corp 電子写真感光体
JPH0374370A (ja) 1989-08-16 1991-03-28 Terumo Corp ピラジン誘導体およびこれを含有する血小板凝集抑制剤または抗炎症剤
JP2597917B2 (ja) 1990-04-26 1997-04-09 富士写真フイルム株式会社 新規な色素形成カプラー及びそれを用いたハロゲン化銀カラー写真感光材料
US5572248A (en) 1994-09-19 1996-11-05 Teleport Corporation Teleconferencing method and system for providing face-to-face, non-animated teleconference environment
WO1997043267A1 (en) 1996-05-11 1997-11-20 Kings College London Pyrazines
JP4026876B2 (ja) 1996-09-05 2007-12-26 日本食品化工株式会社 発光性シクロデキストリン誘導体及びその製造方法
JP2002241379A (ja) 1997-03-21 2002-08-28 Dainippon Pharmaceut Co Ltd ３−オキサジアゾリルキノキサリン誘導体
WO1999044609A1 (en) 1998-03-03 1999-09-10 Merck & Co., Inc. FUSED PIPERIDINE SUBSTITUTED ARYLSULFONAMIDES AS β3-AGONISTS
DE19826671A1 (de) 1998-06-16 1999-12-23 Hoechst Schering Agrevo Gmbh 1,3-Oxazolin- und 1,3-Thiazolin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel
CA2336832A1 (en) 1998-07-16 2000-01-27 Shionogi & Co., Ltd. Pyrimidine derivatives exhibiting antitumor activity
US7023913B1 (en) 2000-06-14 2006-04-04 Monroe David A Digital security multimedia sensor
ES2267492T3 (es) * 1999-02-05 2007-03-16 Debiopharm S.A. Derivados de ciclosporina y procedimiento de preparacion de dichos derivados.
US6738073B2 (en) 1999-05-12 2004-05-18 Imove, Inc. Camera system with both a wide angle view and a high resolution view
US6479504B1 (en) 1999-06-16 2002-11-12 The University Of Iowa Research Foundation Antagonism of immunostimulatory CpG-oligonucleotides by 4-aminoquinolines and other weak bases
US7015954B1 (en) 1999-08-09 2006-03-21 Fuji Xerox Co., Ltd. Automatic video system using multiple cameras
US6660753B2 (en) 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
CN1272328C (zh) 1999-12-17 2006-08-30 希龙公司 糖元合成酶激酶3的基于吡嗪的抑制剂
US6849660B1 (en) 2000-08-01 2005-02-01 Isis Pharmaceuticals, Inc. Antimicrobial biaryl compounds
JP2002072370A (ja) 2000-08-29 2002-03-12 Fuji Photo Optical Co Ltd ペーパーマガジン及び写真焼付装置
JP2002072372A (ja) 2000-09-04 2002-03-12 Fuji Photo Film Co Ltd 画像形成用シート体の切断装置
US6829391B2 (en) 2000-09-08 2004-12-07 Siemens Corporate Research, Inc. Adaptive resolution system and method for providing efficient low bit rate transmission of image data for distributed applications
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
US8085293B2 (en) 2001-03-14 2011-12-27 Koninklijke Philips Electronics N.V. Self adjusting stereo camera system
US6759657B2 (en) 2001-03-27 2004-07-06 Kabushiki Kaisha Toshiba Infrared sensor
JPWO2002080899A1 (ja) * 2001-03-30 2005-01-06 エーザイ株式会社 消化器疾患治療剤
US6469002B1 (en) * 2001-04-19 2002-10-22 Millennium Pharmaceuticals, Inc. Imidazolidine compounds
EP1408986B1 (en) 2001-05-08 2008-09-24 Yale University Proteomimetic compounds and methods
SE0102439D0 (sv) * 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
SE0102438D0 (sv) 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
JP2003074370A (ja) 2001-09-05 2003-03-12 Suzuki Motor Corp エンジンのベルト保護装置
JP2005508321A (ja) * 2001-09-26 2005-03-31 メルク　エンド　カムパニー　インコーポレーテッド 結晶形態のエルタペネムナトリウム
GB0124939D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
US6992087B2 (en) 2001-11-21 2006-01-31 Pfizer Inc Substituted aryl 1,4-pyrazine derivatives
DE60234269D1 (de) 2001-11-21 2009-12-17 Pharmacia & Upjohn Co Llc Substituierte aryl 1,4-pyrazin derivate
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
CA2475633C (en) 2002-02-06 2013-04-02 Vertex Pharmaceuticals Incorporated Heteroaryl compounds useful as inhibitors of gsk-3
CA2476586C (en) 2002-03-13 2011-11-01 Janssen Pharmaceutica N.V. Sulfonyl-derivatives as novel inhibitors of histone deacetylase
GB0206860D0 (en) 2002-03-22 2002-05-01 Glaxo Group Ltd Compounds
TWI319387B (en) 2002-04-05 2010-01-11 Astrazeneca Ab Benzamide derivatives
US7043079B2 (en) 2002-04-25 2006-05-09 Microsoft Corporation “Don't care” pixel interpolation
GB0209715D0 (en) 2002-04-27 2002-06-05 Astrazeneca Ab Chemical compounds
US7704995B2 (en) 2002-05-03 2010-04-27 Exelixis, Inc. Protein kinase modulators and methods of use
CA2484209C (en) 2002-05-03 2013-06-11 Exelixis, Inc. Protein kinase modulators and methods of use
KR20050004214A (ko) 2002-05-31 2005-01-12 에자이 가부시키가이샤 피라졸 화합물 및 이것을 포함하여 이루어지는 의약 조성물
US20040082627A1 (en) 2002-06-21 2004-04-29 Darrow James W. Certain aromatic monocycles as kinase modulators
WO2004000318A2 (en) 2002-06-21 2003-12-31 Cellular Genomics, Inc. Certain amino-substituted monocycles as kinase modulators
WO2004033431A2 (en) 2002-10-04 2004-04-22 Arena Pharmaceuticals, Inc. Hydroxypyrazoles for use against metabolic-related disorders
US20040075741A1 (en) 2002-10-17 2004-04-22 Berkey Thomas F. Multiple camera image multiplexer
US7385626B2 (en) 2002-10-21 2008-06-10 Sarnoff Corporation Method and system for performing surveillance
US20040100560A1 (en) 2002-11-22 2004-05-27 Stavely Donald J. Tracking digital zoom in a digital video camera
SE0203752D0 (sv) 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
SE0203754D0 (sv) 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
ES2502490T3 (es) 2003-02-26 2014-10-03 Sugen, Inc. Compuestos aminoheteroarílicos como inhibidores de proteín quinasas
US7684624B2 (en) 2003-03-03 2010-03-23 Smart Technologies Ulc System and method for capturing images of a target area on which information is recorded
EP1606267B1 (en) 2003-03-11 2008-07-30 Pfizer Products Inc. Pyrazine compounds as transforming growth factor (tgf) inhibitors
US7459454B2 (en) 2003-03-21 2008-12-02 Smithkline Beecham Corporation Aminopyrazine derivatives and compositions
WO2004084824A2 (en) 2003-03-24 2004-10-07 Merck & Co., Inc. Biaryl substituted 6-membered heterocyles as sodium channel blockers
GB2400101A (en) 2003-03-28 2004-10-06 Biofocus Discovery Ltd Compounds capable of binding to the active site of protein kinases
GB2400514B (en) 2003-04-11 2006-07-26 Hewlett Packard Development Co Image capture method
CN1788008A (zh) 2003-05-15 2006-06-14 麦克公司 作为s1p受体激动剂的3－(2－氨基－1－氮杂环基)－5－芳基－1,2,4－噁二唑
WO2004103991A1 (en) 2003-05-20 2004-12-02 'chemical Diversity Research Institute', Ltd. 2-substituted piperidines, focused library and a pharmaceutical compound
US20050123902A1 (en) * 2003-05-21 2005-06-09 President And Fellows Of Harvard College Human papillomavirus inhibitors
PE20050206A1 (es) 2003-05-26 2005-03-26 Schering Ag Composicion farmaceutica que contiene un inhibidor de histona deacetilasa
US7986339B2 (en) 2003-06-12 2011-07-26 Redflex Traffic Systems Pty Ltd Automated traffic violation monitoring and reporting system with combined video and still-image data
JP2005020227A (ja) 2003-06-25 2005-01-20 Pfu Ltd 画像圧縮装置
AR045595A1 (es) 2003-09-04 2005-11-02 Vertex Pharma Composiciones utiles como inhibidores de proteinas quinasas
WO2005034952A2 (en) 2003-10-07 2005-04-21 The Feinstein Institute For Medical Research Isoxazole and isothiazole compounds useful in the treatment of inflammation
US20050116968A1 (en) 2003-12-02 2005-06-02 John Barrus Multi-capability display
WO2005058876A1 (en) 2003-12-16 2005-06-30 Gpc Biotech Ag Pyrazine derivatives as effective compounds against infectious diseases
AU2005215379A1 (en) 2004-02-12 2005-09-01 Merck & Co., Inc. Bipyridyl amides as modulators of metabotropic glutamate receptor-5
US20050276765A1 (en) * 2004-06-10 2005-12-15 Paul Nghiem Preventing skin damage
EP1773807A2 (en) 2004-06-14 2007-04-18 Takeda San Diego, Inc. Kinase inhibitors
JP2008508304A (ja) 2004-07-27 2008-03-21 エスジーエックス ファーマシューティカルズ、インコーポレイテッド 縮合環ヘテロ環キナーゼ調節因子
US7626021B2 (en) 2004-07-27 2009-12-01 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
NZ552866A (en) 2004-08-26 2010-06-25 Pfizer Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
WO2006021886A1 (en) 2004-08-26 2006-03-02 Pfizer Inc. Aminoheteroaryl compounds as protein tyrosine kinase inhibitors
US7730406B2 (en) 2004-10-20 2010-06-01 Hewlett-Packard Development Company, L.P. Image processing system and method
AU2005299501B2 (en) 2004-10-22 2011-03-03 Janssen Pharmaceutica N.V. Aromatic amides as inhibitors of c-fms kinase
EP1828144A2 (en) 2004-11-12 2007-09-05 OSI Pharmaceuticals, Inc. Integrin antagonists useful as anticancer agents
EP1814882A1 (en) 2004-11-22 2007-08-08 Vertex Pharmaceuticals Incorporated Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases
JP4810669B2 (ja) 2004-11-25 2011-11-09 コニカミノルタホールディングス株式会社 有機エレクトロルミネッセンス素子、表示装置及び照明装置
GB0428235D0 (en) 2004-12-23 2005-01-26 Glaxo Group Ltd Novel compounds
KR100994173B1 (ko) 2004-12-27 2010-11-15 알콘, 인코퍼레이티드 녹내장 및 다른 로 키나아제-매개 질환 치료용아미노피라진 유사체
GB0500492D0 (en) 2005-01-11 2005-02-16 Cyclacel Ltd Compound
US7622583B2 (en) 2005-01-14 2009-11-24 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2
GB0501999D0 (en) 2005-02-01 2005-03-09 Sentinel Oncology Ltd Pharmaceutical compounds
CN101163692B (zh) 2005-02-16 2012-01-18 先灵公司 具有cxcr3拮抗活性的杂环取代的哌嗪
EP1874769B1 (de) 2005-04-25 2011-09-14 Merck Patent GmbH Neuartige aza-heterozyklen als kinase-inhibitoren
WO2006124874A2 (en) 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibitors of b-raf kinase
AU2006258101A1 (en) 2005-06-09 2006-12-21 Merck Sharp & Dohme Corp. Inhibitors of checkpoint kinases
AU2006275403A1 (en) 2005-08-02 2007-02-08 Lexicon Pharmaceuticals, Inc. 2-aminoaryl pyridines as protein kinases inhibitors
WO2007015632A1 (en) 2005-08-04 2007-02-08 Cgk Co., Ltd. Atm and atr inhibitor
US7394926B2 (en) 2005-09-30 2008-07-01 Mitutoyo Corporation Magnified machine vision user interface
US7806604B2 (en) 2005-10-20 2010-10-05 Honeywell International Inc. Face detection and tracking in a wide field of view
TW200736260A (en) 2005-11-10 2007-10-01 Smithkline Beecham Corp Inhibitors of Akt activity
ATE452635T1 (de) 2005-12-01 2010-01-15 Hoffmann La Roche Heteroaryl-substituierte piperidin-derivate als l-cpt1-hemmer
WO2007066805A1 (ja) 2005-12-09 2007-06-14 Meiji Seika Kaisha, Ltd. リンコマイシン誘導体およびこれを有効成分とする抗菌剤
JP2009519937A (ja) * 2005-12-14 2009-05-21 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー 無脊椎有害生物防除用イソオキサゾリン
BRPI0620463A2 (pt) 2005-12-22 2011-11-16 Alcon Res Ltd composição farmacêutica oftálmica, compostos, e seus usos
PE20070978A1 (es) 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
ITMI20060311A1 (it) 2006-02-21 2007-08-22 Btsr Int Spa Dispositivo perfezionato di alimentazione di filo o filatio ad una macchina tessile e metodo per attuare tale alimentazione
GB0603684D0 (en) 2006-02-23 2006-04-05 Novartis Ag Organic compounds
WO2007096764A2 (en) 2006-02-27 2007-08-30 Glenmark Pharmaceuticals S.A. Bicyclic heteroaryl derivatives as cannabinoid receptor modulators
TW200800203A (en) 2006-03-08 2008-01-01 Astrazeneca Ab New use
ATE453635T1 (de) 2006-03-22 2010-01-15 Vertex Pharma C-met-proteinkinasehemmer zur behandlung proliferativer erkrankungen
US7574131B2 (en) 2006-03-29 2009-08-11 Sunvision Scientific Inc. Object detection system and method
US7700601B2 (en) 2006-03-31 2010-04-20 Schering Corporation Substituted indazoles of formula 1.0 that are kinase inhibitors
US7629346B2 (en) 2006-06-19 2009-12-08 Hoffmann-La Roche Inc. Pyrazinecarboxamide derivatives as CB1 antagonists
ATE456565T1 (de) 2006-06-22 2010-02-15 Biovitrum Ab Publ Pyridin- und pyrazinderivate als mnk- kinaseinhibitoren
EP2038261A2 (en) 2006-06-22 2009-03-25 Mallinckrodt Inc. Pyrazine derivatives with extended conjugation and uses thereof
EP1900727A1 (en) 2006-08-30 2008-03-19 Cellzome Ag Aminopyridine derivatives as kinase inhibitors
CN101516885A (zh) 2006-09-29 2009-08-26 诺瓦提斯公司 作为pi3k脂质激酶抑制剂的吡唑并嘧啶类化合物
GB0619342D0 (en) 2006-09-30 2006-11-08 Vernalis R&D Ltd New chemical compounds
CN101522626A (zh) 2006-10-04 2009-09-02 霍夫曼-拉罗奇有限公司 作为hdl-胆固醇升高剂的3-吡啶甲酰胺或2-吡嗪甲酰胺衍生物
MX337906B (es) 2006-10-19 2016-03-28 Signal Pharm Llc Compuestos de heteroarilo, composiciones de los mismos, y su uso como inhibidores de proteina cinasas.
WO2008060907A2 (en) 2006-11-10 2008-05-22 Bristol-Myers Squibb Company Pyrrolo-pyridine kinase inhibitors
US20080132698A1 (en) 2006-11-30 2008-06-05 University Of Ottawa Use of N-oxide compounds in coupling reactions
WO2008071456A2 (en) 2006-12-15 2008-06-19 Bayer Schering Pharma Aktiengesellschaft 3-h-pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
WO2008079291A2 (en) 2006-12-20 2008-07-03 Amgen Inc. Substituted heterocycles and methods of use
GB0625659D0 (en) 2006-12-21 2007-01-31 Cancer Rec Tech Ltd Therapeutic compounds and their use
PE20081581A1 (es) 2006-12-21 2008-11-12 Plexxikon Inc COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA
EP2114898A2 (en) 2007-02-16 2009-11-11 Amgen Inc. Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors
BRPI0808523A2 (pt) 2007-03-01 2014-08-19 Novartis Vaccines & Diagnostic Inibidores de pim cinase e métodos de seu uso
JP2008260691A (ja) * 2007-04-10 2008-10-30 Bayer Cropscience Ag 殺虫性アリールイソオキサゾリン誘導体
MY146638A (en) * 2007-04-10 2012-09-14 Bayer Cropscience Ag Insecticidal aryl isoxazoline derivatives
TW200902008A (en) 2007-05-10 2009-01-16 Smithkline Beecham Corp Quinoxaline derivatives as PI3 kinase inhibitors
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
UY31137A1 (es) 2007-06-14 2009-01-05 Smithkline Beecham Corp Derivados de quinazolina como inhibidores de la pi3 quinasa
JP2009027904A (ja) 2007-06-19 2009-02-05 Hitachi Ltd 回転電機
EP2012409A2 (en) 2007-06-19 2009-01-07 Hitachi, Ltd. Rotating electrical machine
WO2008156174A1 (ja) 2007-06-21 2008-12-24 Taisho Pharmaceutical Co., Ltd. ピラジンアミド化合物
EP2170306A1 (en) 2007-06-26 2010-04-07 Lexicon Pharmaceuticals, Inc. Methods of treating serotonin-mediated diseases and disorders
JP2010531358A (ja) 2007-06-27 2010-09-24 メルク・シャープ・エンド・ドーム・コーポレイション ヒストン脱アセチル化酵素阻害剤としてのピリジル及びピリミジニル誘導体
GB0713259D0 (en) 2007-07-09 2007-08-15 Astrazeneca Ab Pyrazine derivatives 954
BRPI0813426A2 (pt) 2007-07-19 2014-12-23 Lundbeck & Co As H Composto, composição farmacêutica, métodos para modular a atividade de um receptor p2x7, para tratar uma condição, para inibir a morte de células gangliônicas retinais, para promover perda de peso,e para determinar a presença ou ausência de receptor p2x7 em uma amostra, preparação farmacêutica acondicionada, uso de composto ou sal ou hidrato do mesmo.
US8293747B2 (en) 2007-07-19 2012-10-23 Merck Sharp & Dohme Corp. Heterocyclic amide compounds as protein kinase inhibitors
JP4792126B2 (ja) 2007-08-01 2011-10-12 ファイザー・インク ピラゾール化合物およびＲａｆ阻害剤としてのその使用
WO2009024825A1 (en) 2007-08-21 2009-02-26 Astrazeneca Ab 2-pyrazinylbenzimidazole derivatives as receptor tyrosine kinase inhibitors
EP2203436A1 (en) 2007-09-17 2010-07-07 Neurosearch A/S Pyrazine derivatives and their use as potassium channel modulators
WO2009053737A2 (en) 2007-10-25 2009-04-30 Astrazeneca Ab Pyridine and pyrazine derivatives useful in the treatment of cell proliferative disorders
JP2011511005A (ja) 2008-02-04 2011-04-07 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド ２−アミノピリジン系キナーゼ阻害薬
BRPI0908494A2 (pt) 2008-02-25 2015-08-11 Hoffmann La Roche Inibidores de pirrolopirazina quinase
DK2250172T3 (da) 2008-02-25 2012-01-16 Hoffmann La Roche Pyrrolopyrazinkinaseinhibitorer
JP5485178B2 (ja) 2008-02-25 2014-05-07 エフ．ホフマン−ラ ロシュ アーゲー ピロロピラジンキナーゼ阻害剤
CN101952296B (zh) 2008-02-25 2013-08-21 霍夫曼-拉罗奇有限公司 吡咯并吡嗪激酶抑制剂
TW200940537A (en) 2008-02-26 2009-10-01 Astrazeneca Ab Heterocyclic urea derivatives and methods of use thereof
EP2265574A1 (en) 2008-02-29 2010-12-29 Array Biopharma, Inc. N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer
US8268834B2 (en) 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
US8110576B2 (en) 2008-06-10 2012-02-07 Plexxikon Inc. Substituted pyrrolo[2,3b]pyrazines and methods for treatment of raf protein kinase-mediated indications
GB0814364D0 (en) 2008-08-05 2008-09-10 Eisai London Res Lab Ltd Diazaindole derivatives and their use in the inhibition of c-Jun N-terminal kinase
DK2767537T3 (da) * 2008-08-06 2017-06-19 Medivation Technologies Inc Dihydropyridophthalazinon-hæmmere af poly(adp-ribose)polymerase (parp)
JP5576370B2 (ja) 2008-08-06 2014-08-20 ファイザー・インク Ｃｈｋ−１阻害剤としての６置換２−ヘテロシクリルアミノピラジン化合物
JP2010077286A (ja) 2008-09-26 2010-04-08 Aica Kogyo Co Ltd シリコーン樹脂組成物および粘着フィルム
EP2350045A1 (en) 2008-10-21 2011-08-03 Vertex Pharmaceuticals Incorporated C-met protein kinase inhibitors
EP2370424A1 (en) 2008-11-10 2011-10-05 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
CA2744498C (en) 2008-11-25 2017-10-24 University Of Rochester Mlk inhibitors and methods of use
JP5431495B2 (ja) 2008-12-05 2014-03-05 エフ．ホフマン−ラ ロシュ アーゲー ピロロピラジニル尿素キナーゼ阻害薬
SG172248A1 (en) 2008-12-19 2011-07-28 Vertex Pharma Pyrazine derivatives useful as inhibitors of atr kinase
UY32351A (es) * 2008-12-22 2010-07-30 Astrazeneca Ab Compuestos de pirimidinil indol para uso como inhibidores de atr
JP5575799B2 (ja) 2008-12-22 2014-08-20 アレイ バイオファーマ、インコーポレイテッド ７−フェノキシクロマンカルボン酸誘導体
RU2505540C2 (ru) 2008-12-23 2014-01-27 Эббви Инк. Антивирусные соединения
WO2010087430A1 (ja) 2009-01-30 2010-08-05 富山化学工業株式会社 Ｎ－アシルアントラニル酸誘導体またはその塩
JP5353279B2 (ja) 2009-02-06 2013-11-27 Ｊｎｃ株式会社 セレンテラミド又はその類縁体の製造方法
WO2010093425A1 (en) 2009-02-11 2010-08-19 Sepracor Inc. Histamine h3 inverse agonists and antagonists and methods of use thereof
CN101537007A (zh) 2009-03-18 2009-09-23 中国医学科学院血液病医院（血液学研究所） N-(噻吩-2)吡唑并[1,5-a]嘧啶-3-甲酰胺类化合物在制备抗恶性肿瘤药物方面的应用
US20120065247A1 (en) 2009-03-27 2012-03-15 Discoverybiomed, Inc. Modulating ires-mediated translation
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
SG177606A1 (en) 2009-07-13 2012-03-29 Widex As A hearing aid adapted fordetecting brain waves and a method for adapting such a hearing aid
JP2012533551A (ja) 2009-07-15 2012-12-27 アボット・ラボラトリーズ ピロロピラジン系キナーゼ阻害薬
AP3534A (en) 2009-08-07 2016-01-13 Dow Agrosciences Llc Pesticidal compositions
JP2011042639A (ja) 2009-08-24 2011-03-03 Kowa Co ビフェニルピラジン化合物及びこれを有効成分として含有するエリスロポエチン産生促進剤
CN101671336B (zh) 2009-09-23 2013-11-13 辽宁利锋科技开发有限公司 芳杂环并嘧啶衍生物和类似物及其制备方法和用途
DE102009043260A1 (de) 2009-09-28 2011-04-28 Merck Patent Gmbh Pyridinyl-imidazolonderivate
MX353257B (es) 2009-10-06 2018-01-05 Millennium Pharmaceuticals Inc Star Compuestos heterociclicos utiles como inhibidores de proteina cinasa-1 dependiente de 3-fosfoinositido (pdk1).
PT2526090E (pt) 2010-01-18 2015-11-30 Medicines For Malaria Venture Mmv Novos agentes antimaláricos
US8518945B2 (en) 2010-03-22 2013-08-27 Hoffmann-La Roche Inc. Pyrrolopyrazine kinase inhibitors
CA2794428A1 (en) * 2010-04-08 2011-10-13 Pfizer Inc. Substituted 3,5-diphenyl-isoxazoline derivatives as insecticides and acaricides
EP2558866B1 (en) 2010-04-15 2016-08-17 Tracon Pharmaceuticals, Inc. Potentiation of anti-cancer activity through combination therapy with ber pathway inhibitors
JP2013525476A (ja) 2010-05-04 2013-06-20 ファイザー・インク Ａｌｋ阻害剤としての複素環式誘導体
US8969356B2 (en) 2010-05-12 2015-03-03 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
EP2569287B1 (en) 2010-05-12 2014-07-09 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
MX2012013081A (es) 2010-05-12 2013-05-09 Vertex Pharma Compuestos utiles como inhibidores de cinasa atr.
JP2013529200A (ja) 2010-05-12 2013-07-18 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ阻害剤として有用な化合物
JP5856151B2 (ja) * 2010-05-12 2016-02-09 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼ阻害剤として有用な２−アミノピリジン誘導体
US8962631B2 (en) 2010-05-12 2015-02-24 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
CA2798970A1 (en) 2010-05-20 2011-11-24 F. Hoffmann-La Roche Ag Pyrrolopyrazine derivatives as syk and jak inhibitors
WO2011144585A1 (en) 2010-05-20 2011-11-24 F. Hoffmann-La Roche Ag Pyrrolo [2, 3 - b] pyrazine - 7 - carboxamide derivatives and their use as jak and syk inhibitors
MX2013000103A (es) 2010-06-23 2013-06-13 Vertex Pharma Derivados de pirrolo-pirazina utiles como inhibidores de cinasa art.
CN102311396B (zh) 2010-07-05 2015-01-07 暨南大学 一种吡嗪类衍生物和其制备方法及在制药中的应用
EP2407478A1 (en) 2010-07-14 2012-01-18 GENETADI Biotech, S.L. New cyclotetrapeptides with pro-angiogenic properties
JP5782238B2 (ja) 2010-07-30 2015-09-24 ルネサスエレクトロニクス株式会社 電圧検出回路及びその制御方法
WO2012121939A2 (en) 2011-03-04 2012-09-13 Locus Pharmaceuticals, Inc. Aminopyrazine compounds
WO2012121992A1 (en) 2011-03-04 2012-09-13 Lexicon Pharmaceuticals, Inc. Mst1 kinase inhibitors and methods of their use
CN103562190A (zh) * 2011-03-22 2014-02-05 佐蒂斯有限责任公司 作为抗寄生虫药的异噁唑啉衍生物
MX2013011450A (es) 2011-04-05 2014-02-03 Vertex Pharma Compuestos de aminopirazina utiles como inhibidores de la cinasa ataxia telangiectasia mutada y rad3 relacionados (atr).
WO2012158785A1 (en) 2011-05-17 2012-11-22 Principia Biopharma Inc. Azaindole derivatives as tyrosine kinase inhibitors
JP2014520161A (ja) 2011-06-22 2014-08-21 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ阻害剤として有用な化合物
US9096602B2 (en) 2011-06-22 2015-08-04 Vertex Pharmaceuticals Incorporated Substituted pyrrolo[2,3-B]pyrazines as ATR kinase inhibitors
US9309250B2 (en) 2011-06-22 2016-04-12 Vertex Pharmaceuticals Incorporated Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors
EP2751088B1 (en) 2011-09-30 2016-04-13 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
SG10201602515QA (en) 2011-09-30 2016-05-30 Vertex Pharma Treating pancreatic cancer and non-small cell lung cancer with atr inhibitors
US8853217B2 (en) 2011-09-30 2014-10-07 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
PT2940017T (pt) 2011-09-30 2019-10-31 Vertex Pharma Processos para a produção de compostos úteis como inibidores de atr quinase
AU2012315611A1 (en) 2011-09-30 2014-04-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
JP2015502925A (ja) 2011-11-09 2015-01-29 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼの阻害剤として有用なピラジン化合物
US8841450B2 (en) 2011-11-09 2014-09-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
EP2776422A1 (en) 2011-11-09 2014-09-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
EP2776421A1 (en) 2011-11-09 2014-09-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
WO2013071094A1 (en) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
NZ700580A (en) 2012-04-05 2016-07-29 Vertex Pharma Compounds useful as inhibitors of atr kinase and combination therapies thereof
CN103373996A (zh) 2012-04-20 2013-10-30 山东亨利医药科技有限责任公司 作为crth2受体拮抗剂的二并环衍生物
WO2014055756A1 (en) 2012-10-04 2014-04-10 Vertex Pharmaceuticals Incorporated Method for measuring atr inhibition mediated increases in dna damage
US8912198B2 (en) 2012-10-16 2014-12-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
FI4190786T3 (fi) 2012-12-07 2025-05-23 Vertex Pharma Atr-kinaasin estäjinä käyttökelpoisia yhdisteitä
JP6096005B2 (ja) 2013-02-26 2017-03-15 リンテック株式会社 シート剥離装置および剥離方法
EP3077397B1 (en) 2013-12-06 2019-09-18 Vertex Pharmaceuticals Inc. 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof
HRP20200186T1 (hr) 2014-06-05 2020-05-29 Vertex Pharmaceuticals Inc. Radioaktivno obilježeni derivati 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-karboksamid spojeva koji se koriste kao inhibitori atr kinaze, priprava navedenih spojeva i njihovi različiti čvrsti oblici
JP6936007B2 (ja) 2014-06-17 2021-09-15 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ｃｈｋ１阻害剤とａｔｒ阻害剤との組み合わせを使用してがんを処置する方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017061519A (ja) * 2011-09-30 2017-03-30 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼの阻害剤として有用な化合物を作製するためのプロセス

Also Published As

Publication number Publication date
IL284849A (en) 2021-08-31
TWI625324B (zh) 2018-06-01
PL2940017T3 (pl) 2020-03-31
IN2014KN00929A (OSRAM) 2015-08-21
RU2018147217A (ru) 2019-01-18
AR088092A1 (es) 2014-05-07
ZA201402625B (en) 2015-10-28
US9862709B2 (en) 2018-01-09
KR20190099346A (ko) 2019-08-26
US10208027B2 (en) 2019-02-19
JP2019172684A (ja) 2019-10-10
HK1201259A1 (en) 2015-08-28
PT2940017T (pt) 2019-10-31
WO2013049726A3 (en) 2013-06-06
EP2940017B1 (en) 2019-08-28
JP2017226676A (ja) 2017-12-28
MX353461B (es) 2018-01-15
EP3878851A1 (en) 2021-09-15
TW201825454A (zh) 2018-07-16
JP6317800B2 (ja) 2018-04-25
KR102184246B1 (ko) 2020-12-01
BR112014007721A2 (pt) 2017-04-25
EP3608316A1 (en) 2020-02-12
IL265459A (en) 2019-05-30
CA2850566A1 (en) 2013-04-04
CA3124539A1 (en) 2013-04-04
KR102013133B1 (ko) 2019-08-22
EP2751097A2 (en) 2014-07-09
IL231771A0 (en) 2014-05-28
AU2019210688B2 (en) 2021-05-27
US10822331B2 (en) 2020-11-03
IL284849B1 (en) 2023-04-01
US9035053B2 (en) 2015-05-19
KR20140090175A (ko) 2014-07-16
BR112014007721B1 (pt) 2022-11-01
RU2014117635A (ru) 2015-11-10
HK1218415A1 (en) 2017-02-17
CN106496173A (zh) 2017-03-15
SG11201401093WA (en) 2014-04-28
NZ737090A (en) 2019-05-31
TW201331164A (zh) 2013-08-01
AU2017206213B2 (en) 2019-05-23
RS59337B1 (sr) 2019-10-31
TW201800407A (zh) 2018-01-01
EP2940017A3 (en) 2016-02-17
CN103987709A (zh) 2014-08-13
HRP20191641T1 (hr) 2019-12-13
HUE046429T2 (hu) 2020-03-30
NZ623089A (en) 2016-05-27
MX2014003794A (es) 2015-01-16
US20150274710A1 (en) 2015-10-01
CN103987709B (zh) 2016-09-28
AU2017206213A1 (en) 2017-08-03
ES2751741T3 (es) 2020-04-01
AU2012315615A1 (en) 2014-04-17
IL284849B2 (en) 2023-08-01
JP2014532054A (ja) 2014-12-04
WO2013049726A2 (en) 2013-04-04
TWI625328B (zh) 2018-06-01
NZ719122A (en) 2017-12-22
AU2019210688A1 (en) 2019-08-22
US20130184292A1 (en) 2013-07-18
EP2940017A2 (en) 2015-11-04
CA2850566C (en) 2022-05-03
US20190202818A1 (en) 2019-07-04
SG10201606774UA (en) 2016-10-28
TWI675834B (zh) 2019-11-01
US20180244662A1 (en) 2018-08-30
RU2677292C2 (ru) 2019-01-16
JP2017061519A (ja) 2017-03-30

Similar Documents

Publication Publication Date Title
JP6317800B2 (ja) Ａｔｒキナーゼの阻害剤として有用な化合物を作製するためのプロセス
HK1218415B (en) Processes for making compounds useful as inhibitors of atr kinase
HK1235771A1 (en) Processes for making compounds useful as inhibitors of atr kinase
HK1201259B (en) Processes for making compounds useful as inhibitors of atr kinase

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150925

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150925

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160428

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160513

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160812

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161114

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170130

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170411

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170627

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170904

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170914

R150 Certificate of patent or registration of utility model

Ref document number: 6212045

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees